RxDoctor Payments Data

Joy Okwuwa, MD

Nephrology · Midland, TXNPI 1194135574

Payments from drug & device makers

$949in general payments, 2019–2025

Across 40 payments — averaging $23.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$265
  • AstraZeneca$219
  • Boehringer Ingelheim$118
  • Fresenius USA Marketing, Inc.$112
  • Aurinia Pharma U.S., Inc.$76
  • Vifor Pharma, Inc.$38
  • plus $121 from 4 others

What the payments were for

  • Speaking & faculty fees$15016%
  • Food & beverage$79984%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$949 in reported general payments places this provider in the 35th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$223,037
Medicare patients
426
Services billed
1,653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide95$332,271
AuryxiaFerric Citrate36$72,818
JardianceEmpagliflozin57$71,415
FarxigaDapagliflozin Propanediol17$16,596
Sevelamer Carbonate73$10,479
LokelmaSodium Zirconium Cyclosilicate17$7,969
Bumetanide56$2,327
Calcium Acetate25$2,326
Nifedipine ErNifedipine28$2,139
Midodrine Hcl29$1,745
Allopurinol119$840
Potassium Citrate ErPotassium Citrate11$757
Hydralazine Hcl46$667
Tamsulosin Hcl75$654
Losartan Potassium78$536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$112$332,27195 claims
Akebia Therapeutics IncAuryxia$35$72,81836 claims
Boehringer IngelheimJardiance$118$71,41557 claims
AstraZenecaFarxiga, Lokelma$219$24,56634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Midland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →